Share this article
Share this article
ResearchAndMarkets.com s offering.
This report features an extensive study of the current market landscape and the future potential of sterile fill/finish services for small molecule drugs. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
Small molecule drugs account for nearly 90% of the contemporary therapeutics pipeline. In fact, in 2019, the FDA s Center for Drug Evaluation and Research approved 48 small molecule drugs, representing 70% of the new molecular entities (NMEs) clearing regulatory review in the same year. Given that the demand for small molecule drugs is still on the rise, the importance of contract manufacturing and third party services is also increasing in the pharmaceutical industry. Sterile fill/finish is considered among the most crucial steps in the pharmaceutical production process. In fact, aseptic conditions during fill/finish operations are not only esse